Asterias: BioTime Acquires Two ClinicalStage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and ImmunoOncology

BioTime Inc and Asterias Biotherapeutics Inc announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias that are not